<DOC>
	<DOCNO>NCT00810199</DOCNO>
	<brief_summary>This 2 arm study compare 2 treatment strategy base tocilizumab combination methotrexate placebo patient moderate severe rheumatoid arthritis . Patients receive methotrexate treatment randomize receive either ) tocilizumab 8 mg intravenous ( iv ) every 4 week + methotrexate orally ( po ) weekly b ) tocilizumab 8 mg iv every 4 week + placebo po weekly . After first 24 week blind treatment , treatment adjustment ( increase decrease treatment intensity ) may introduce interval , base response . The anticipated time study treatment 3 year , target sample size approximately 470 patient .</brief_summary>
	<brief_title>A Study Tocilizumab Methotrexate Treatment Strategies ( Adding Tocilizumab Methotrexate Versus Switching Tocilizumab ) Patients With Active Rheumatoid Arthritis With Inadequate Response Prior Methotrexate Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , ≥ 18 year age ; moderate severe active rheumatoid arthritis ( Disease Activity Score ( DAS28 ) &gt; 4.4 ) ; inadequate response methotrexate ; stable dose ≥ 15mg/week methotrexate least 6 week . prior treatment biologic ; Rheumatoid arthritis ( RA ) functional class IV ; know active current history recurrent bacterial , viral , fungal , mycobacterial infection ; evidence active malignant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>